A trio of scientists is being honored for research contributions that helped lead to the development of Trikafta, a…
Articles by Marisa Wexler, MS
The Cystic Fibrosis Foundation is investing up to €6.5 million (about $7.6 million) to support the development of virus-based…
SPL84, an investigational inhalation therapy designed to treat cystic fibrosis (CF) caused by a specific mutation called 3849+10 kb…
The first participants have been dosed in a clinical trial that’s testing some of Sionna Therapeutics’ investigational treatments for…
The U.S. Food and Drug Administration (FDA) has granted two new designations to CMTX-101, an antibody-based therapy Clarametyx Biosciences…
Grants that provide financial assistance for nutrition may help people with cystic fibrosis (CF) maintain a healthy body weight,…
Men with cystic fibrosis (CF) are generally knowledgeable about how their disease affects fertility, but they still want to…
Health Canada has approved the next-generation CFTR modulator therapy Alyftrek for people 6 years and older with cystic…
A lack of stability in a specific region of the CFTR protein may explain why certain people with cystic…
Two experimental CFTR modulator therapies being developed by Sionna Therapeutics are able to improve the function of the most…